Table 1.
Baseline Characteristics Before and After Propensity Score Matching.
| Variables | Unmatched Cohort | Matched Cohort | ||||
|---|---|---|---|---|---|---|
| Statin Group, n = 135 | Nonstatin Group, n = 859 | P Value | Statin Group, n = 133 | Nonstatin Group, n = 133 | P Value | |
| Statin dosage, mg/d, mean (SD) | 18.2 (10) | 0 | <.001 | 18.2 (10) | 0 | <.001 |
| Sex: male, n (%) | 82 (60.7%) | 548 (63.6%) | .515 | 81 (60.9%) | 80 (60.2%) | .900 |
| Age, mean (SD) | 68.5 (7.6) | 62.6 (10.2) | <.001 | 68.6 (7.6) | 67. (8.0) | .182 |
| BMI, mean (SD) | 24.3 (2.7) | 23.8 (2.9) | .046 | 24.3 (2.7) | 24.3 (2.7) | .863 |
| ASA, n (%) | <.001 | .442 | ||||
| 1 | 13 (9.6%) | 255 (29.6%) | 12 (9.0%) | 18 (13.0%) | ||
| 2 | 92 (68.1%) | 525 (61.0%) | 91 (68.4%) | 83 (62.4%) | ||
| 3 | 30 (22.2%) | 81 (9.4%) | 30 (22.6%) | 32 (24.1%) | ||
| Histologic type, % | .694 | .710 | ||||
| Squamous Cell | 33 (24.4%) | 210 (24.4%) | 32 (24.4%) | 32 (24.4%) | ||
| Adenocarcinoma | 87 (64.4%) | 531 (61.8%) | 86 (64.4%) | 84 (63.0%) | ||
| Othersa | 15 (11.1%) | 118 (13.7%) | 15 (11.1%) | 17 (12.6%) | ||
| VATS, n (%) | 33 (24.4%) | 310 (86.4%) | .009 | 32 (24.1%) | 37 (27.8%) | .484 |
| Operation, n (%) | .874 | .311 | ||||
| Lobectomy | 119 (88.1%) | 749 (87.0%) | 118 (88.7%) | 115 (86.5%) | ||
| Segmentectomy, wedge resection | 16 (11.9%) | 112 (13.0%) | 15 (11.3%) | 18 (13.5%) | ||
| Surgery time, minutes, mean (SD) | 177.9 (86.4) | 188.8 (73.8) | .126 | 178.5 (86.7) | 170.4 (61.4) | .401 |
| Hypertension, n (%) | 54 (40.0%) | 138 (16.0%) | <.001 | 54 (40.6%) | 53 (39.8%) | .900 |
| Diabetes mellitus, n (%) | 26 (19.3%) | 57 (6.6%) | <.001 | 26 (19.5%) | 24 (18.0%) | .754 |
| Cerebrovascular disease, n (%) | 16 (11.9%) | 32 (3.7%) | <.001 | 16 (12.0%) | 17 (12.8%) | .852 |
| Ischemic heart disease, n (%) | 27 (20.0%) | 26 (3.0%) | <.001 | 27 (20.3%) | 19 (14.3%) | .195 |
| Tumor, % | .063 | .961 | ||||
| T1 | 79 (58.5%) | 414 (48.1%) | 78 (58.6%) | 77 (57.9%) | ||
| T2 | 48 (35.6%) | 345 (40.1%) | 47 (35.3%) | 46 (34.6%) | ||
| T3 | 6 (4.4%) | 61 (7.1%) | 6 (4.5%) | 7 (5.3%) | ||
| T4 | 2 (1.5%) | 41 (4.8%) | 2 (1.5%) | 3 (2.3%) | ||
| Node, % | .086 | .837 | ||||
| N0 | 110 (81.5%) | 610 (71.0%) | 108 (81.2%) | 106 (79.7%) | ||
| N1 | 14 (10.4%) | 140 (16.3%) | 14 (10.5%) | 17 (12.8%) | ||
| N2 | 11 (8.1%) | 110 (12.7%) | 11 (8.3%) | 10 (7.5%) | ||
| Adjuvant chemotherapy, n (%) | 6 (4.4%) | 76 (8.8%) | .085 | 6 (4.5%) | 8 (6.0%) | .583 |
| Adjuvant radiotherapy, n (%) | 16 (11.9%) | 159 (18.5%) | .060 | 15 (11.3%) | 17 (12.8%) | .706 |
Abbreviations: ASA, American Society of Anesthesiologists; BMI, body mass index; SD, standard deviation; VATS, video-assisted thoracic surgery.
a Others: large cell type, sarcomatoid lung cancer.